Scientific Article
previous document  unige:29858  next document
add to browser collection
Title

P-selectin: a common therapeutic target for cardiovascular disorders, inflammation and tumour metastasis

Authors
Ludwig, Ralf J.
Schon, Michael P.
Published in Expert Opinion On Therapeutic Targets. 2007, vol. 11, no. 8, p. 1103-1117
Abstract P-selectin belongs to the family of selectin adhesion molecules, and is expressed by platelets and endothelial cells on stimulation. This pattern of expression may indicate an involvement of this molecule in inflammation and coagulation. Data from mice lacking P-selectin expression confirmed this assumption. In addition, a key role of P-selectin in the formation of tumour metastases has been established. Apparently unrelated, clinical experience has pointed towards a detrimental interaction of inflammation and cancer with thromboembolic diseases and vice versa. Therefore, targeting molecules such as P-selectin contributing to coagulation, inflammation and metastasis may offer novel therapeutic strategies to treat chronic inflammatory diseases and metastatic cancer. The authors aim to critically evaluate the contribution of P-selectin in these diseases, and discuss the value of therapeutic inhibition of P-selectin functions in coagulation, inflammation and metastasis.
Keywords AnimalsAntineoplastic Agents/*administration & dosageCardiovascular Diseases/drug therapy/*metabolism/*pathologyDrug Delivery Systems/*methodsHumansInflammation Mediators/*administration & dosageNeoplasm Metastasis/*drug therapy/*pathologyP-Selectin/*metabolism/physiology
Identifiers
PMID: 17665981
Full text
Citation
(ISO format)
LUDWIG, Ralf J., SCHON, Michael P., BOEHNCKE, Wolf-Henning. P-selectin: a common therapeutic target for cardiovascular disorders, inflammation and tumour metastasis. In: Expert Opinion On Therapeutic Targets, 2007, vol. 11, n° 8, p. 1103-1117. https://archive-ouverte.unige.ch/unige:29858

177 hits

0 download

Update

Deposited on : 2013-09-20

Export document
Format :
Citation style :